November 16, 2022 06:38 AM ESTUpdated 11:41 AM

Updated: Picking up the pieces after lead drug imploded, Rafael Holdings gives up on early R&D in favor of deals

Amber Tong

In the months since Rafael Holdings’ lead drug flunked two Phase III trials — in metastatic pancreatic cancer and acute myeloid leukemia — the little biotech has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Picking up the pieces after lead drug imploded, Rafael Holdings gives up on early R&D in favor of deals

Amber Tong

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Vertex makes money from sickle cell therapy Casgevy

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Up­dat­ed: Pick­ing up the pieces af­ter lead drug im­plod­ed, Rafael Hold­ings gives up on ear­ly R&D in fa­vor of deals

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: Picking up the pieces after lead drug imploded, Rafael Holdings gives up on early R&D in favor of deals